
Dr Eiffe is a medicinal chemist with over ten years' experience in the biotech industry. Her career in drug development has encompassed everything from bench chemistry, to in silico drug design, to the preparation of regulatory submissions and patent applications, through to the management of chemistry manufacturing projects from the laboratory scale to GMP. Dr Eiffe's current focus is designing small molecules that target isoforms of the actin binding protein, tropomyosin, as well as managing the anti-tropomyosin drug development program at TroBio Therapeutics.